XERS Stock Analysis: Xeris Pharmaceuticals | NASDAQ

Hypoglycemia, Periodic Paralysis, Cushings Syndrome, Hypothyroidism

Total Rating 44

Safety 35

Buy Signal -0.20

Drug Manufacturers - Specialty & Generic
Industry Rotation: -4.6

Market Cap: 1.55B
Avg Turnover: 13.1M

Risk 3d forecast

Volatility63.1%

VaR 5^th Pctl9.42%

VaR vs Median-8.31%

Reward TTM

Sharpe Ratio0.50

Rel. Str. IBD78.3

Rel. Str. Peer Group68.1

Character TTM

Beta0.495

Beta Downside-0.139

Hurst Exponent0.488

Drawdowns 3y

Max DD47.20%

CAGR/Max DD1.14

CAGR/Mean DD2.76

EPS (Earnings per Share)

Last SUE: -1.38
Qual. Beats: -1

Revenue

Rev. CAGR: 34.30%
Rev. Trend: 99.4%

Last SUE: 0.90
Qual. Beats: 2

Warnings

High Debt/EBITDA With Thin Interest Coverage

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Tailwinds

No distinct edge detected

Seasonality 8.1 years of data

Jan -2.0% 21

Feb +3.3% 12

Mar -4.5% 6

Apr +0.8% 9

May +1.7% 9

Jun -0.0% 2

Jul +1.1% 14

Aug +9.8% 10

Sep -1.7% 36

Oct -0.6% 6

Nov +1.0% 6

Dec +1.4% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: XERS Xeris Pharmaceuticals

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a commercial-stage biopharmaceutical company headquartered in Chicago, Illinois, and incorporated in 2005. The company focuses on developing and commercializing therapies for chronic endocrine and neurological diseases, operating within the specialty pharmaceuticals segment of the healthcare sector.

Its marketed portfolio includes Gvoke, a ready-to-use liquid-stable glucagon for severe hypoglycemia; Keveyis, indicated for primary periodic paralysis and its variants; and Recorlev, a cortisol synthesis inhibitor approved for endogenous hypercortisolemia in adult Cushings syndrome patients. These products are largely aimed at rare or underserved endocrine and neurological conditions, a common focus among small-cap specialty biopharma firms seeking differentiated, high-margin therapeutic niches.

Xeris is also advancing XP-8121, a once-weekly subcutaneous levothyroxine candidate currently in Phase 3 clinical development for hypothyroidism. As a small-cap pharmaceutical company that went public in June 2018, Xeris relies on a combination of product revenue, pipeline progression, and regulatory milestones to drive long-term value.

Headlines to Watch Out For

Gvoke glucagon revenue growth accelerates year over year
Recorlev uptake drives Cushings syndrome franchise expansion
Cash burn raises dilution risk amid pipeline development spending

Piotroski VR-10 (Strict) 5.0

Net Income: -17.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA 18.46 > 1.0
NWC/Revenue: 25.40% < 20% (prev 36.75%; Δ -11.35% < -1%)
CFO/TA 0.14 > 3% & CFO 56.6m > Net Income -17.2m
Net Debt (204.5m) to EBITDA (16.4m): 12.46 < 3
Current Ratio: 1.45 > 1.5 & < 3
Outstanding Shares: last quarter (172.8m) vs 12m ago 10.80% < -2%
Gross Margin: 83.34% > 18% (prev 81.14%; Δ 2.21% > 0.5%)
Asset Turnover: 89.85% > 50% (prev 73.51%; Δ 16.34% > 0%)
Interest Coverage Ratio: 0.14 > 6 (EBIT TTM 3.93m / Interest Expense TTM 28.3m)

Altman Z'' -4.14

A: 0.21 (Total Current Assets 274.8m - Total Current Liabilities 189.6m) / Total Assets 411.9m
B: -1.70 (Retained Earnings -700.2m / Total Assets 411.9m)
C: 0.01 (EBIT TTM 3.93m / Avg Total Assets 373.3m)
D: -0.02 (Book Value of Equity -9.73m / Total Liabilities 421.6m)
Altman-Z'' = -4.14 = D

Beneish M -3.12

DSRI: 0.80 (Receivables 58.1m/53.0m, Revenue 335.4m/246.0m)
GMI: 0.97 (GM 81.14% / 83.34%)
AQI: 0.74 (AQ_t 0.27 / AQ_t-1 0.36)
SGI: 1.36 (Revenue 335.4m / 246.0m)
TATA: -0.18 (NI -17.2m - CFO 56.6m) / TA 411.9m)
Beneish M = -3.12 (Cap -4..+1) = AA

What is the price of XERS shares?

As of August 17, 2026, the stock is trading at USD 8.60 with a total of 1,353,520 shares traded. Over the past week, the price has changed by +8.45%, over one month by -1.04%, over three months by +43.09% and over the past year by +16.85%.

Current recommended Stop Loss: 7.90 (which is 8.1% or 1.8 ATR below the current price).

Is XERS a buy, sell or hold?

Xeris Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XERS.

StrongBuy: 4
Buy: 1
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the XERS price?

Analysts Target Price	11.3	31.3%

Xeris Pharmaceuticals (XERS) - Fundamental Data Overview as of 14 August 2026

Market Cap USD = 1.55b (1.55b USD * 1.0 USD.USD)
P/E Forward = 99.0099
P/S = 4.6149
P/B = 107.6774
Revenue TTM = 335.4m USD
EBIT TTM = 3.93m USD
EBITDA TTM = 16.4m USD
Long Term Debt = 188.8m USD (from longTermDebt, last quarter)
Short Term Debt = 70.1m USD (from shortTermDebt, last quarter)
Debt = 326.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 36.9m
Net Debt = 204.5m USD (calculated: Debt 326.3m - CCE 121.7m)
Enterprise Value = 1.75b USD (1.55b + Debt 326.3m - CCE 121.7m)
Interest Coverage Ratio = 0.14 (Ebit TTM 3.93m / Interest Expense TTM 28.3m)
EV/FCF = 31.65x (Enterprise Value 1.75b / FCF TTM 55.4m)
FCF Yield = 3.16% (FCF TTM 55.4m / Enterprise Value 1.75b)
FCF Margin = 16.51% (FCF TTM 55.4m / Revenue TTM 335.4m)
Net Margin = -5.12% (Net Income TTM -17.2m / Revenue TTM 335.4m)
Gross Margin = 83.34% ((Revenue TTM 335.4m - Cost of Revenue TTM 55.9m) / Revenue TTM)
Gross Margin QoQ = 86.41% (prev 84.02%)
Tobins Q-Ratio = 4.25 (Enterprise Value 1.75b / Total Assets 411.9m)
Interest Expense / Debt = 8.66% (Interest Expense 28.3m / Debt 326.3m)
Taxrate = 0.0% (0.0 / 554k)
NOPAT = 3.93m (EBIT 3.93m * (1 - 0.00%))
Current Ratio = 1.45 (Total Current Assets 274.8m / Total Current Liabilities 189.6m)
Debt / Equity = -33.52 (negative equity) (Debt 326.3m / totalStockholderEquity, last quarter -9.73m)
Debt / EBITDA = 12.46 (Net Debt 204.5m / EBITDA 16.4m)
Debt / FCF = 3.69 (Net Debt 204.5m / FCF TTM 55.4m)
Total Stockholder Equity = 4.03m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.60% (Net Income -17.2m / Total Assets 411.9m)
RoE = -426.3% (Net Income TTM -17.2m / Total Stockholder Equity 4.03m)
RoCE = 2.04% (EBIT 3.93m / Capital Employed (Equity 4.03m + L.T.Debt 188.8m))
RoIC = 1.43% (NOPAT 3.93m / Invested Capital 275.7m)
WACC = 7.88% (E(1.55b)/V(1.87b) * Re(7.72%) + D(326.3m)/V(1.87b) * Rd(8.66%) * (1-Tc(0.0)))
Discount Rate = 7.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.75 | Cagr: 9.63%
[DCF] Terminal Value 75.44% ; FCFF base≈55.4m ; Y1≈55.6m ; Y5≈58.9m
[DCF] Fair Price = 3.90 (EV 916.2m - Net Debt 204.5m = Equity 711.6m / Shares 182.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.38 | # QB: -1
Revenue Correlation: 99.38 | Revenue CAGR: 34.30% | SUE: 0.90 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.02 | Chg30d=-150.00% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.00 | Chg30d=-102.36% | Revisions=-25% | GrowthEPS=+0.0% | GrowthRev=+32.8%
EPS next Year (2027-12-31): EPS=0.39 | Chg30d=-0.64% | Revisions=-25% | GrowthEPS=+11811.7% | GrowthRev=+24.1%
[Analyst] Revisions Ratio: -50% (up=0, down=3)